This biologic therapy is currently approved in Canada and the U.S. for the treatment of adolescents with rheumatoid arthritis. It has also been approved for children with juvenile rheumatoid arthritis, and has been studied in children with psonasis. It is approved in Europe for children aged 8 and up with psoriasis.
Etanercept targets and blocks the inflammatory messenger TNF-alpha, which is made by cells in the immune system and sends faulty signals to the skin and joints. Patients with psoriasis and psoriatic arthritis produce too much TNF-alpha, which results in inflammation, causing red, scaly skin lesions and swollen, tender joints. Etanercept reduces inflammation by blocking TNF-alpha's inflammatory message and works like a sponge to reduce the amount of TNF-alpha in the skin and joints.
Latest Treatment For Psoriasis |